Lidocaine Aguettant (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the rapid influx of sodium ions that initiates an action potential. This stabilizes the nerve membrane, halting impulse conduction and producing a reversible loss of sensation in the treated area.

The appropriate dose of Lidocaine Aguettant is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical context. Dosing recommendations are provided in the product labeling and must be individualized for each patient.

Safety data for Lidocaine Aguettant in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Lidocaine has a rapid onset and moderate duration of action, making it suitable for short procedures. Compared with longer‑acting agents such as bupivacaine, lidocaine provides quicker recovery of sensation but may require repeat dosing for prolonged surgeries. Its safety profile is well‑established, and it is often preferred when a fast, controllable block is needed.

Store the sterile solution at ambient temperature, preferably below 25 °C, in its original packaging. Protect it from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for any particulate matter or discoloration before use.

Lidocaine Aguettant is administered by infiltration, intradermal injection, or intravenous infusion, depending on the clinical indication. The injection technique follows standard aseptic procedures, and the volume injected is calculated based on the desired anesthetic effect and patient-specific factors.

Serious risks include central nervous system toxicity (seizures, confusion), cardiac toxicity (arrhythmias, cardiac arrest), severe allergic reactions such as anaphylaxis, methemoglobinemia, and profound hypotension. Prompt recognition and supportive management are essential if these events occur.

Patients with known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled epilepsy, or significant hepatic impairment should avoid using Lidocaine Aguettant unless a specialist determines that benefits outweigh risks.